| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IRMDIRadimed Corporation | 1.29B | 101.53 | 67.69 | 11.71% | 26.31% | 21.54% | 1.36% | 0.00 |
| BRKRBruker Corporation | 7.47B | 49.14 | 64.66 | 13.56% | -0.61% | -0.84% | 1.82% | 1.24 |
| STESTERIS plc | 25.94B | 264.25 | 42.62 | 6.24% | 12.07% | 9.8% | 3% | 0.33 |
| FONRFONAR Corporation | 114.8M | 18.61 | 15.13 | 1.43% | 7.08% | 4.62% | 6.49% | 0.24 |
| PACBPacific Biosciences of California, Inc. | 712.5M | 2.36 | -2.21 | -23.19% | -325.8% | -13.95% | 1.33 | |
| HYPRHyperfine, Inc. | 101.82M | 1.24 | -2.21 | 16.84% | -378.17% | -149.05% | 0.01 | |
| IRIXIRIDEX Corporation | 22.69M | 1.32 | -2.44 | -6.17% | -10.04% | -108.67% | 2.21 | |
| MASS908 Devices Inc. | 196.89M | 5.44 | -2.57 | 18.72% | -7.17% | -3.03% | 0.06 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 114.71M | 104.45M | 101.94M | 112.96M | 117.24M | 138.14M | 130.58M | 97.95M | 106.34M | 174.43M |
| Revenue Growth % | -0.01% | -0.09% | -0.02% | 0.11% | 0.04% | 0.18% | -0.05% | -0.25% | 0.09% | 0.64% |
| Cost of Goods Sold | 46.63M | 46.01M | 49.95M | 51.31M | 52.96M | 54.82M | 61.21M | 60.9M | 55.89M | 90.17M |
| COGS % of Revenue | 0.41% | 0.44% | 0.49% | 0.45% | 0.45% | 0.4% | 0.47% | 0.62% | 0.53% | 0.52% |
| Gross Profit | 68.08M | 58.44M | 51.98M | 61.65M | 64.28M | 83.33M | 69.37M | 37.05M | 50.45M | 84.26M |
| Gross Margin % | 0.59% | 0.56% | 0.51% | 0.55% | 0.55% | 0.6% | 0.53% | 0.38% | 0.47% | 0.48% |
| Gross Profit Growth % | -0.08% | -0.14% | -0.11% | 0.19% | 0.04% | 0.3% | -0.17% | -0.47% | 0.36% | 0.67% |
| Operating Expenses | 122.22M | 131.63M | 110.34M | 109.81M | 116.12M | 134.36M | 136.83M | 153.26M | 127.05M | 259.5M |
| OpEx % of Revenue | 1.07% | 1.26% | 1.08% | 0.97% | 0.99% | 0.97% | 1.05% | 1.56% | 1.19% | 1.49% |
| Selling, General & Admin | 82.96M | 93.21M | 79.52M | 79.78M | 84.48M | 97.9M | 98.89M | 102.28M | 87.54M | 156.61M |
| SG&A % of Revenue | 0.72% | 0.89% | 0.78% | 0.71% | 0.72% | 0.71% | 0.76% | 1.04% | 0.82% | 0.9% |
| Research & Development | 39.26M | 38.41M | 30.83M | 30.03M | 31.64M | 36.46M | 37.94M | 37.38M | 25.95M | 62.41M |
| R&D % of Revenue | 0.34% | 0.37% | 0.3% | 0.27% | 0.27% | 0.26% | 0.29% | 0.38% | 0.24% | 0.36% |
| Other Operating Expenses | -1.16M | -1.17M | 385K | 637K | 0 | 0 | 0 | 13.59M | 13.56M | 40.48M |
| Operating Income | -50.16M | -73.19M | -58.36M | -48.16M | -51.84M | -51.04M | -67.46M | -116.2M | -76.6M | -175.24M |
| Operating Margin % | -0.44% | -0.7% | -0.57% | -0.43% | -0.44% | -0.37% | -0.52% | -1.19% | -0.72% | -1% |
| Operating Income Growth % | 0.03% | -0.46% | 0.2% | 0.17% | -0.08% | 0.02% | -0.32% | -0.72% | 0.34% | -1.29% |
| EBITDA | -34.04M | -55.25M | -40.06M | -31.66M | -36.03M | -35.11M | -51.89M | -101.18M | -61.42M | -158.38M |
| EBITDA Margin % | -0.3% | -0.53% | -0.39% | -0.28% | -0.31% | -0.25% | -0.4% | -1.03% | -0.58% | -0.91% |
| EBITDA Growth % | 0.29% | -0.62% | 0.27% | 0.21% | -0.14% | 0.03% | -0.48% | -0.95% | 0.39% | -1.58% |
| D&A (Non-Cash Add-back) | 16.11M | 17.94M | 18.3M | 16.5M | 15.8M | 15.92M | 15.57M | 15.03M | 15.18M | 16.86M |
| EBIT | -48.98M | -74.36M | -57.98M | -47.53M | -62.43M | -50.53M | -59.84M | -188.6M | -69.64M | -135M |
| Net Interest Income | -5.81M | -5.82M | -5.82M | -13.89M | -4.28M | -3.57M | -3.82M | -2.1M | 1M | 16.88M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.23M | 5.57M | 20.2M |
| Interest Expense | 5.81M | 5.82M | 5.82M | 13.89M | 4.28M | 3.57M | 3.82M | 4.33M | 4.57M | 3.32M |
| Other Income/Expense | -4.63M | -6.99M | -5.44M | -13.26M | -14.87M | -3.06M | 3.8M | -76.72M | 2.4M | 36.92M |
| Pretax Income | -54.79M | -80.18M | -63.8M | -61.42M | -66.7M | -54.1M | -63.66M | -192.93M | -74.2M | -138.31M |
| Pretax Margin % | -0.48% | -0.77% | -0.63% | -0.54% | -0.57% | -0.39% | -0.49% | -1.97% | -0.7% | -0.79% |
| Income Tax | -1.48M | -4.19M | -3.26M | -2.41M | -1.92M | -1.08M | -4.42M | -2.83M | 452K | 573K |
| Effective Tax Rate % | 0.97% | 0.95% | 0.95% | 0.96% | 0.97% | 0.98% | 0.93% | 0.99% | 1.01% | 1% |
| Net Income | -53.31M | -75.98M | -60.53M | -59.01M | -64.79M | -53.02M | -59.24M | -190.1M | -74.66M | -138.88M |
| Net Margin % | -0.46% | -0.73% | -0.59% | -0.52% | -0.55% | -0.38% | -0.45% | -1.94% | -0.7% | -0.8% |
| Net Income Growth % | -0.01% | -0.43% | 0.2% | 0.03% | -0.1% | 0.18% | -0.12% | -2.21% | 0.61% | -0.86% |
| Net Income (Continuing) | -53.31M | -75.98M | -60.53M | -59.01M | -64.79M | -53.02M | -59.24M | -190.1M | -74.66M | -138.88M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.86 | -2.62 | -1.84 | -1.49 | -0.97 | -0.74 | -0.78 | -2.43 | -0.94 | -0.52 |
| EPS Growth % | 0.02% | -0.41% | 0.3% | 0.19% | 0.35% | 0.24% | -0.05% | -2.12% | 0.61% | 0.45% |
| EPS (Basic) | -1.86 | -2.62 | -1.84 | -1.49 | -0.97 | -0.74 | -0.78 | -2.43 | -0.94 | -0.52 |
| Diluted Shares Outstanding | 28.71M | 29.01M | 32.98M | 39.65M | 66.78M | 72.04M | 75.79M | 78.31M | 79.16M | 352.67M |
| Basic Shares Outstanding | 28.71M | 29.01M | 32.98M | 39.65M | 66.78M | 72.04M | 75.79M | 78.31M | 79.16M | 352.67M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 144.09M | 96.67M | 94.8M | 127.11M | 96.1M | 117.66M | 72.07M | 208.81M | 158.22M | 375.88M |
| Cash & Short-Term Investments | 94.97M | 59.43M | 63.14M | 95.4M | 58.64M | 68.52M | 28.45M | 165.78M | 114.89M | 292.87M |
| Cash Only | 29.12M | 35.05M | 58.06M | 95.4M | 21.66M | 68.52M | 28.45M | 81.31M | 51.7M | 166.73M |
| Short-Term Investments | 65.86M | 24.39M | 5.08M | 0 | 36.98M | 0 | 0 | 84.47M | 63.19M | 126.15M |
| Accounts Receivable | 25.46M | 14.61M | 15.05M | 16.65M | 18.98M | 25.42M | 18.32M | 17.28M | 19.66M | 33.61M |
| Days Sales Outstanding | 81 | 51.06 | 53.89 | 53.8 | 59.09 | 67.17 | 51.21 | 64.39 | 67.48 | 70.32 |
| Inventory | 17.92M | 20.11M | 15.09M | 13M | 13.88M | 19.69M | 20.82M | 21.47M | 20.53M | 40.74M |
| Days Inventory Outstanding | 140.3 | 159.57 | 110.24 | 92.49 | 95.68 | 131.1 | 124.19 | 128.7 | 134.09 | 164.9 |
| Other Current Assets | 0 | 2.52M | 1.53M | 2.05M | 0 | 0 | 16K | 4.28M | 3.13M | 8.66M |
| Total Non-Current Assets | 226.97M | 209.72M | 192.55M | 176.54M | 168.72M | 207.09M | 203.15M | 181.5M | 164.85M | 236.46M |
| Property, Plant & Equipment | 15.26M | 16.52M | 12.3M | 8.82M | 12.92M | 55.65M | 65.15M | 59.53M | 54.85M | 71.38M |
| Fixed Asset Turnover | 7.52x | 6.32x | 8.29x | 12.80x | 9.08x | 2.48x | 2.00x | 1.65x | 1.94x | 2.44x |
| Goodwill | 104.11M | 104.11M | 104.11M | 104.11M | 104.11M | 106.56M | 106.38M | 106.25M | 106.32M | 111.3M |
| Intangible Assets | 91.05M | 79.8M | 68.6M | 57.4M | 49.13M | 42.22M | 27.93M | 12.6M | 1.4M | 28.95M |
| Long-Term Investments | 6.49M | 0 | 0 | 0 | 0 | 0 | 1M | 0 | 0 | 0 |
| Other Non-Current Assets | 10.06M | 9.29M | 7.54M | 6.21M | 2.56M | 2.66M | 3.69M | 3.11M | 2.29M | 24.83M |
| Total Assets | 371.06M | 306.39M | 287.35M | 303.65M | 264.81M | 324.76M | 275.21M | 390.31M | 323.07M | 612.34M |
| Asset Turnover | 0.31x | 0.34x | 0.35x | 0.37x | 0.44x | 0.43x | 0.47x | 0.25x | 0.33x | 0.28x |
| Asset Growth % | -0.09% | -0.17% | -0.06% | 0.06% | -0.13% | 0.23% | -0.15% | 0.42% | -0.17% | 0.9% |
| Total Current Liabilities | 30.08M | 29.5M | 33.47M | 37.58M | 32.82M | 54.25M | 49.57M | 43.44M | 109.33M | 65.89M |
| Accounts Payable | 6.09M | 3.97M | 4.21M | 4.03M | 5.15M | 9.22M | 10.6M | 7.91M | 9.24M | 12.28M |
| Days Payables Outstanding | 47.7 | 31.47 | 30.77 | 28.64 | 35.5 | 61.39 | 63.22 | 47.43 | 60.32 | 49.72 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 6.84M | 2.08M | 59.53M | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 3.55M | 12.37M | 10.54M | 7.62M | 3.84M | 11.21M | 8.67M | 3.96M | 12.05M | 14.71M |
| Current Ratio | 4.79x | 3.28x | 2.83x | 3.38x | 2.93x | 2.17x | 1.45x | 4.81x | 1.45x | 5.70x |
| Quick Ratio | 4.19x | 2.60x | 2.38x | 3.04x | 2.50x | 1.81x | 1.03x | 4.31x | 1.26x | 5.09x |
| Cash Conversion Cycle | 173.6 | 179.15 | 133.36 | 117.65 | 119.27 | 136.88 | 112.17 | 145.66 | 141.26 | 185.51 |
| Total Non-Current Liabilities | 226.08M | 223.66M | 222.94M | 193.95M | 78.38M | 131.46M | 131.05M | 428.33M | 361.79M | 74.73M |
| Long-Term Debt | 195.68M | 194.95M | 195.24M | 172.06M | 53.82M | 54.22M | 64.21M | 62.81M | 3.98M | 299K |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 4.32M | 38.18M | 37.55M | 34.08M | 30.37M | 26.47M |
| Deferred Tax Liabilities | 23.59M | 21.14M | 16.92M | 13.71M | 11.49M | 8.7M | 4.33M | 1.05M | 841K | 1.08M |
| Other Non-Current Liabilities | 2.4M | 3.26M | 5.83M | 1.85M | 573K | 1.33M | 882K | 312.21M | 312.32M | 6.96M |
| Total Liabilities | 256.16M | 253.16M | 256.42M | 231.53M | 111.2M | 185.71M | 180.62M | 471.78M | 471.12M | 140.62M |
| Total Debt | 195.68M | 194.95M | 195.24M | 172.06M | 59.98M | 95.38M | 111.65M | 102.66M | 98.21M | 33M |
| Net Debt | 166.57M | 159.91M | 137.18M | 76.66M | 38.32M | 26.86M | 83.2M | 21.35M | 46.51M | -133.73M |
| Debt / Equity | 1.70x | 3.66x | 6.31x | 2.39x | 0.39x | 0.69x | 1.18x | - | - | 0.07x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -8.64x | -12.58x | -10.02x | -3.47x | -12.11x | -14.29x | -17.65x | -26.83x | -16.77x | -52.85x |
| Total Equity | 114.9M | 53.23M | 30.93M | 72.12M | 153.61M | 139.05M | 94.6M | -81.47M | -148.05M | 471.72M |
| Equity Growth % | -0.24% | -0.54% | -0.42% | 1.33% | 1.13% | -0.09% | -0.32% | -1.86% | -0.82% | 4.19% |
| Book Value per Share | 4.00 | 1.84 | 0.94 | 1.82 | 2.30 | 1.93 | 1.25 | -1.04 | -1.87 | 1.34 |
| Total Shareholders' Equity | 114.9M | 53.23M | 30.93M | 72.12M | 153.61M | 139.05M | 94.6M | -81.47M | -148.05M | 471.72M |
| Common Stock | 29K | 29K | 39K | 49K | 70K | 75K | 77K | 80K | 83K | 396K |
| Retained Earnings | -363.49M | -439.48M | -500.2M | -558.85M | -623.64M | -676.76M | -736M | -926.1M | -1B | -1.19B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -563K | -5.98M | -46.47M |
| Accumulated OCI | -1.14M | -760K | -574K | -687K | -582K | 112K | -907K | -1.9M | -2.22M | 1.23M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -34.7M | -39.1M | -24.1M | -25.2M | -35.21M | -15.42M | -44.06M | -89.37M | -43.29M | -143.45M |
| Operating CF Margin % | -0.3% | -0.37% | -0.24% | -0.22% | -0.3% | -0.11% | -0.34% | -0.91% | -0.41% | -0.82% |
| Operating CF Growth % | -0.53% | -0.13% | 0.38% | -0.05% | -0.4% | 0.56% | -1.86% | -1.03% | 0.52% | -2.31% |
| Net Income | -53.31M | -75.98M | -60.53M | -59.01M | -64.79M | -53.02M | -59.24M | -190.1M | -74.66M | -138.88M |
| Depreciation & Amortization | 16.11M | 17.94M | 18.61M | 16.57M | 17.74M | 15.92M | 16.2M | 15.03M | 15.18M | 16.86M |
| Stock-Based Compensation | 16.83M | 13.86M | 9.09M | 11.02M | 11.39M | 14.45M | 16.1M | 14.88M | 13.12M | 31.73M |
| Deferred Taxes | -2.33M | 0 | 0 | 141K | 0 | 212K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -3.76M | 339K | -468K | 8.55M | 16.96M | 4.6M | 886K | 83.17M | 1.28M | -41.08M |
| Working Capital Changes | -8.23M | 4.75M | 9.2M | -2.48M | -16.51M | 2.41M | -18.01M | -12.35M | 1.79M | -12.08M |
| Change in Receivables | -2.76M | 10.52M | -554K | -1.79M | -2.08M | -7.63M | 6.73M | 1.06M | -2.99M | 8.97M |
| Change in Inventory | -3.74M | -3.39M | 4.6M | 1.49M | -3.05M | -8.64M | -4.78M | -8.47M | -4.91M | -9.88M |
| Change in Payables | 769K | -2.27M | 585K | -294K | 0 | 3.36M | 0 | 0 | 1.62M | 0 |
| Cash from Investing | 25.74M | 45.1M | 17.66M | 4.72M | -39.3M | 39.98M | -11.95M | -88.13M | 20.24M | 363.17M |
| Capital Expenditures | -10.65M | -5.07M | -1.62M | -372K | -2.53M | -12.72M | -13.26M | -3.83M | -2.83M | -8.36M |
| CapEx % of Revenue | 0.09% | 0.05% | 0.02% | 0% | 0.02% | 0.09% | 0.1% | 0.04% | 0.03% | 0.05% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 2.33M | 50.17M | -50K | 5.09M | -36.77M | 21.04M | 1.32M | -84.3M | 0 | 92.88M |
| Cash from Financing | 5.3M | 76K | 29M | 57.66M | 2.79M | 20.86M | 15.96M | 230.76M | -6.81M | -102.62M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 5.3M | 187K | 204K | -1.81M | 245K | 631K | 8.25M | 213.37M | 827K | 1.52M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -45.35M | -44.16M | -25.71M | -25.57M | -37.74M | -28.13M | -57.33M | -93.19M | -46.12M | -151.81M |
| FCF Margin % | -0.4% | -0.42% | -0.25% | -0.23% | -0.32% | -0.2% | -0.44% | -0.95% | -0.43% | -0.87% |
| FCF Growth % | -0.51% | 0.03% | 0.42% | 0.01% | -0.48% | 0.25% | -1.04% | -0.63% | 0.51% | -2.29% |
| FCF per Share | -1.58 | -1.52 | -0.78 | -0.64 | -0.57 | -0.39 | -0.76 | -1.19 | -0.58 | -0.43 |
| FCF Conversion (FCF/Net Income) | 0.65x | 0.51x | 0.40x | 0.43x | 0.54x | 0.29x | 0.74x | 0.47x | 0.58x | 1.03x |
| Interest Paid | 5.54M | 5.53M | 5.53M | 5.53M | 3.54M | 3.09M | 3.15M | 3.49M | 3.82M | 3.09M |
| Taxes Paid | 189K | 355K | 245K | 321K | 0 | 521K | 0 | 0 | 801K | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -40.19% | -90.39% | -143.84% | -114.53% | -57.41% | -36.23% | -50.71% | -2895.85% | - | -85.82% |
| Return on Invested Capital (ROIC) | -12.67% | -22.2% | -22.96% | -22.8% | -22.82% | -21.39% | -29.44% | -148.13% | - | -111.17% |
| Gross Margin | 59.35% | 55.95% | 50.99% | 54.57% | 54.83% | 60.32% | 53.13% | 37.83% | 47.44% | 48.31% |
| Net Margin | -46.48% | -72.75% | -59.38% | -52.24% | -55.26% | -38.38% | -45.36% | -194.08% | -70.2% | -79.62% |
| Debt / Equity | 1.70x | 3.66x | 6.31x | 2.39x | 0.39x | 0.69x | 1.18x | - | - | 0.07x |
| Interest Coverage | -8.64x | -12.58x | -10.02x | -3.47x | -12.11x | -14.29x | -17.65x | -26.83x | -16.77x | -52.85x |
| FCF Conversion | 0.65x | 0.51x | 0.40x | 0.43x | 0.54x | 0.29x | 0.74x | 0.47x | 0.58x | 1.03x |
| Revenue Growth | -1.5% | -8.95% | -2.4% | 10.82% | 3.79% | 17.83% | -5.47% | -24.99% | 8.57% | 64.03% |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Product And Service | - | - | - | - | - | - | - | 96.17M | 105.18M | 169.7M |
| Product And Service Growth | - | - | - | - | - | - | - | - | 9.37% | 61.35% |
| Product | - | - | - | 93.65M | 95.42M | 99.94M | 100.38M | 72.45M | 79.2M | 88.57M |
| Product Growth | - | - | - | - | 1.89% | 4.75% | 0.43% | -27.82% | 9.31% | 11.83% |
| Service | - | - | - | 19.31M | 21.28M | 22.58M | 25.92M | 23.71M | 25.98M | 81.13M |
| Service Growth | - | - | - | - | 10.16% | 6.12% | 14.78% | -8.51% | 9.56% | 212.29% |
| Consumables | - | - | - | 48.16M | 45.41M | - | 57.88M | 46.79M | 41.74M | 60.06M |
| Consumables Growth | - | - | - | - | -5.70% | - | - | -19.16% | -10.80% | 43.90% |
| Instruments | - | - | - | 45.49M | 50M | - | 42.5M | 25.66M | 37.46M | 28.5M |
| Instruments Growth | - | - | - | - | 9.92% | - | - | -39.61% | 45.96% | -23.91% |
| Collaboration and Other Revenue | - | - | - | - | - | - | - | - | - | 4.73M |
| Collaboration and Other Revenue Growth | - | - | - | - | - | - | - | - | - | - |
| Product and Service, Other | - | - | - | - | - | 6.76M | 1.73M | 964K | 1.16M | - |
| Product and Service, Other Growth | - | - | - | - | - | - | -74.41% | -44.25% | 20.54% | - |
| License | - | - | - | - | - | - | 147K | 964K | - | - |
| License Growth | - | - | - | - | - | - | - | 555.78% | - | - |
| Collaboration Revenue | - | - | - | - | - | - | 2.56M | 818K | - | - |
| Collaboration Revenue Growth | - | - | - | - | - | - | - | -68.03% | - | - |
| Grant | - | - | - | - | - | - | 1.58M | - | - | - |
| Grant Growth | - | - | - | - | - | - | - | - | - | - |
| Grant Revenue | - | - | - | - | 550K | - | - | - | - | - |
| Grant Revenue Growth | - | - | - | - | - | - | - | - | - | - |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Americas | - | - | - | 51.17M | 47.02M | 74.59M | 63.88M | 43.98M | 46.2M | 93.46M |
| Americas Growth | - | - | - | - | -8.12% | 58.64% | -14.36% | -31.15% | 5.03% | 102.32% |
| EMEA | - | - | - | 36.62M | 40.02M | 37.78M | 42.72M | 33.14M | 36.2M | 52.32M |
| EMEA Growth | - | - | - | - | 9.30% | -5.62% | 13.09% | -22.44% | 9.25% | 44.52% |
| Asia Pacific | 10.93M | 18.48M | 20M | 25.18M | 30.2M | 25.78M | 23.98M | 20.83M | 23.94M | 28.65M |
| Asia Pacific Growth | - | 69.14% | 8.26% | 25.84% | 19.97% | -14.64% | -6.98% | -13.14% | 14.94% | 19.66% |
| UNITED STATES | 55.15M | 52.64M | 45.82M | - | - | - | - | - | - | - |
| UNITED STATES Growth | - | -4.55% | -12.95% | - | - | - | - | - | - | - |
| Europe | 36.77M | 29.74M | 32.64M | - | - | - | - | - | - | - |
| Europe Growth | - | -19.13% | 9.76% | - | - | - | - | - | - | - |
| CHINA | - | 11.1M | 11.1M | - | - | - | - | - | - | - |
| CHINA Growth | - | - | 0.00% | - | - | - | - | - | - | - |
| JAPAN | 6.04M | - | - | - | - | - | - | - | - | - |
| JAPAN Growth | - | - | - | - | - | - | - | - | - | - |
| Other Geographical Countries | 5.57M | - | - | - | - | - | - | - | - | - |
| Other Geographical Countries Growth | - | - | - | - | - | - | - | - | - | - |
Standard BioTools Inc. (LAB) reported $128.8M in revenue for fiscal year 2024. This represents a 201% increase from $42.9M in 2011.
Standard BioTools Inc. (LAB) grew revenue by 64.0% over the past year. This is strong growth.
Standard BioTools Inc. (LAB) reported a net loss of $128.3M for fiscal year 2024.
Standard BioTools Inc. (LAB) has a return on equity (ROE) of -85.8%. Negative ROE indicates the company is unprofitable.
Standard BioTools Inc. (LAB) had negative free cash flow of $98.4M in fiscal year 2024, likely due to heavy capital investments.